{"id":"6023854775b5","type":"article","url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","title":"2024 ACC beslispad: klinische beoordeling en trajectmanagement bij HFpEF","title_en":"2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.002","source_url":"https://doi.org/10.1016/j.jacc.2024.06.002","authors":["Steven M Hollenberg","Lynne Warner Stevenson","Tariq Ahmad","Biykem Bozkurt","Javed Butler","Leslie L Davis","Mark H Drazner","James N Kirkpatrick","Alanna A Morris","Robert Lee Page","Hasan Khalid Siddiqi","Alan B Storrow","John R Teerlink"],"significance":8,"published":"2024-09-24","source_date":"2024-09-24","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"The 2024 ACC Expert Consensus provided a structured decision pathway for clinical assessment, management, and trajectory of HFpEF patients during hospitalization, including fluid management, SGLT2 inhibitor initiation, and transition to outpatient care.","created":"2026-07-03T10:31:11Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC expert consensus document geeft een gestructureerd beslispad voor de klinische beoordeling en het trajectmanagement van HFpEF-patiënten. Het integreert SGLT2-remmers, GLP-1-agonisten en gewichtsmanagement.","abstract_original":""}